Aripiprazol en el autismo: seguridad y tolerancia
Descargas
Publicado
2012-03-30
Cómo citar
Vidal Formoso, M., & Montañés Rada, F. (2012). Aripiprazol en el autismo: seguridad y tolerancia. Revista De Psiquiatría Infanto-Juvenil, 29(1), 25–33. Recuperado a partir de https://aepnya.eu/index.php/revistaaepnya/article/view/238
Número
Sección
Artículo de revisión
Palabras clave:
Aripiprazol, tratamiento, niños, trastorno autistaResumen
El objetivo de este estudio es hacer una revisión sobre la eficacia y seguridad de aripiprazol en el tratamiento de los síntomas de irritabilidad asociados al trastorno autista. También se revisa la mejoría en otros síntomas de la escala Aberrant Behavior Checklist (ABC). Para ello hemos revisado tres estudios. Dos son aleatorizados, doble ciego y multicéntricos, 8 semanas de duración, que evaluaban la eficacia de aripiprazol a dosis fijas (5mg/d, 10mg/d, 15mg/d) y a dosis flexibles (2-15mg/d) comparados con placebo. El tercer estudio fue un análisis post hoc de los dos anteriores y evaluó el efecto del aripiprazol en los 58 ítems de la escala ABC. Los resultados fueron significativos con aripiprazol en comparación con placebo en los siguientes ítems de la escala ABC y con todas las dosis de aripiprazol usadas: cambios rápidos de humor, gritos, patadas, movimientos repetitivos, bullicioso, constantemente corre o salta y tiende a ser excesivamente activos. Con la dosis de 15 mg /d se obtuvieron resultados significativos en un mayor número de items.
Descargas
Los datos de descargas todavía no están disponibles.
Citas
1. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry. 2005;162(6):1133–1141
2. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118(1). Available at:1/e139
3. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–321
4. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004; 114 (5). Available at: 5/e634
5. Broadstock M, Doughty C. The effectiveness of pharmacological therapies for young people and adults with autism spectrum disorder (ASD):a critical appraisal of the literature. Christchurch: New Zealand Health Technology Assessment; 2003. p. 77.
6. BarnardL, Young A H, Pearson J, Geddes J, O’Brien G. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002; 16:93-101.37.
7. McCracken J T, McGough J, Shah B, Cronin P, Hong D, Aman M G, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314-21.
8. Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J ClinPsychopharmacol.2008;28(4):441–446
9. Findling RL, Robb A, Nyilas M, et al. A multiplecenter, randomized, double-blind, placebo-con trolled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11):1432–1441
10. Biederman J, Mick E, Spencer T, et al. An openlabel trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr. 2007;12(9): 683–689
11. Biederman J, McDonnell MA, Wozniak J, et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr. 2005;10(2):141–148
12. Valicenti - McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. j Child Adolesc Psychopharmacol. 2006;16: 549-560.
13. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004; 14:455-463.
14. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG: A placebo controlled fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110-1119, 2009.
15. Owen R, Sikich l, Marcus R.N. Corey P, George L, McQuade R.D., Findling R.L. Aripiprazol in the treatment of irritability in children and adolescents with autistic disorder. Pedriatrics 2009; 124; 1533- 1540.
16. Aman M G, Kasper W, Manos G, Mathew S, Marcus R, Owen R, Mankoski R. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. Journal of child and adolescent psychopharmacology. 2010. Volume 20, Number 5:415-422.
17. Aman MG, Singh NN. Aberrant Behavior Checklist: Manual. East Aurora, NY: Slosson Educational Publications; 1986
18. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview–Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord.1994;24(5):659–685
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 212:11-19.
20. G. Barnes TR. A rating scale for drug-induced akathisia. Br j Psychiatry. 1989; 154:672-676.
21. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976: 534-537. US Department of Health, Education, and Welfare publication (ADM) 76-338.
2. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118(1). Available at:1/e139
3. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–321
4. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004; 114 (5). Available at: 5/e634
5. Broadstock M, Doughty C. The effectiveness of pharmacological therapies for young people and adults with autism spectrum disorder (ASD):a critical appraisal of the literature. Christchurch: New Zealand Health Technology Assessment; 2003. p. 77.
6. BarnardL, Young A H, Pearson J, Geddes J, O’Brien G. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002; 16:93-101.37.
7. McCracken J T, McGough J, Shah B, Cronin P, Hong D, Aman M G, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314-21.
8. Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J ClinPsychopharmacol.2008;28(4):441–446
9. Findling RL, Robb A, Nyilas M, et al. A multiplecenter, randomized, double-blind, placebo-con trolled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11):1432–1441
10. Biederman J, Mick E, Spencer T, et al. An openlabel trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr. 2007;12(9): 683–689
11. Biederman J, McDonnell MA, Wozniak J, et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr. 2005;10(2):141–148
12. Valicenti - McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. j Child Adolesc Psychopharmacol. 2006;16: 549-560.
13. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004; 14:455-463.
14. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG: A placebo controlled fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110-1119, 2009.
15. Owen R, Sikich l, Marcus R.N. Corey P, George L, McQuade R.D., Findling R.L. Aripiprazol in the treatment of irritability in children and adolescents with autistic disorder. Pedriatrics 2009; 124; 1533- 1540.
16. Aman M G, Kasper W, Manos G, Mathew S, Marcus R, Owen R, Mankoski R. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. Journal of child and adolescent psychopharmacology. 2010. Volume 20, Number 5:415-422.
17. Aman MG, Singh NN. Aberrant Behavior Checklist: Manual. East Aurora, NY: Slosson Educational Publications; 1986
18. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview–Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord.1994;24(5):659–685
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 212:11-19.
20. G. Barnes TR. A rating scale for drug-induced akathisia. Br j Psychiatry. 1989; 154:672-676.
21. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976: 534-537. US Department of Health, Education, and Welfare publication (ADM) 76-338.
© 2021 AEPNyA Todos los derechos reservados
